BerGenBio ASA (BRRGF) has released an update.
BerGenBio ASA has successfully completed a share capital reduction from NOK 390,871,160 to NOK 39,087,116, by lowering the nominal value per share from NOK 10 to NOK 1, now resulting in an equal number of shares and voting rights. The Norwegian biopharmaceutical company, which specializes in developing drugs for aggressive diseases such as cancer and severe respiratory infections, has registered the change without objections following a six-week creditor notice period. BerGenBio, listed on the Oslo Stock Exchange under the ticker BGBIO, continues its focus on its lead candidate, bemcentinib, for treating STK11 mutated NSCLC and severe respiratory infections.
For further insights into BRRGF stock, check out TipRanks’ Stock Analysis page.
